Issue 8/2005
Content (10 Articles)
Real-world trials to answer real-world questions
Nick Freemantle, Lawrence Blonde, Bjorn Bolinder, Robert A. Gerber, F. D. Richard Hobbs, Luc Martinez, Stuart Ross
Pharmaceutical policy regarding generic drugs in Belgium
Steven Simoens, Kristien De Bruyn, Marc Bogaert, Gert Laekeman
Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer
Elizabeth A. Calhoun, Glen T. Schumock, June M. McKoy, Simon Pickard, Karen A. Fitzner, Elizabeth A. Heckinger, Eowyn F. Powell, Kathyrn R. McCaffrey, Charles L. Bennett
Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK
Louis S. Matza, Kristina Secnik, Sally Mannix, F. Randy Sallee
Societal discounting of health effects in cost-effectiveness analyses
Suzanne Polinder, Willem Jan Meerding, Job van Exel, Werner Brouwer
Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme
Janne A. Martikainen, Akseli Kivioja, Taru Hallinen, Pia Vihinen
Cost of illness and its predictors for Parkinson’s disease in Germany
Annika E. Spottke, Martin Reuter, Olaf Machat, Bernhard Bornschein, Sonja von Campenhausen, Karin Berger, Rudolf Koehne-Volland, Jürgen Rieke, Alexander Simonow, Dirk Brandstaedter, Uwe Siebert, Wolfgang H. Oertel, Gudrun Ulm, Richard Dodel
An economic evaluation of rizatriptan in the treatment of migraine
Melissa Thompson, Marek Gawel, Brigitte Desjardins, Nicole Ferko, Daniel Grima
The authors’ reply
Anthony O’Hagan, Christopher McCabe, Ron Akehurst, Alan Brennan, Andrew Briggs, Karl Claxton, Elisabeth Fenwick, Dennis Fryback, Mark Sculpher, David Spiegelhalter, Andrew Willan